NEO Stock Overview
Operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
NeoGenomics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.00 |
| 52 Week High | US$19.12 |
| 52 Week Low | US$6.08 |
| Beta | 1.6 |
| 1 Month Change | -9.40% |
| 3 Month Change | -40.70% |
| 1 Year Change | -47.12% |
| 3 Year Change | 8.40% |
| 5 Year Change | -70.47% |
| Change since IPO | 207.69% |
Recent News & Updates
Recent updates
PanTracer Launch And MRD Collaboration Will Strengthen Future Cancer Testing Leadership
Mar 23 NeoGenomics' strategic investments and collaborations are expected to enhance customer experiences, boost test volumes, and strengthen competitive positioning in MRD monitoring and Heme testing.NeoGenomics, Inc.'s (NASDAQ:NEO) Stock Retreats 28% But Revenues Haven't Escaped The Attention Of Investors
Mar 08
NeoGenomics: Decent Fundamentals, But Still Overvalued
Feb 28Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt
Feb 18What You Can Learn From NeoGenomics, Inc.'s (NASDAQ:NEO) P/S After Its 29% Share Price Crash
Jan 14NeoGenomics, Inc. (NASDAQ:NEO) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable
Nov 23Is NeoGenomics (NASDAQ:NEO) A Risky Investment?
Oct 16Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%
Aug 01Is NeoGenomics (NASDAQ:NEO) A Risky Investment?
Jul 15Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues
Mar 30Investor Optimism Abounds NeoGenomics, Inc. (NASDAQ:NEO) But Growth Is Lacking
Dec 26Is NeoGenomics (NASDAQ:NEO) A Risky Investment?
Aug 23Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)
Jul 16NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt
Apr 18We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt
Jan 10NeoGenomics: Market Punishment Continues, But Looks Justified
Sep 30NeoGenomics grants CEO restricted shares, stock options
Aug 17Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt
Aug 10NeoGenomics rises ~14% on strong Q2 result
Aug 09NeoGenomics gets new CEO
Jul 21NeoGenomics: Refrain From Portfolio Allocation, Negligible Upside Potential
Jun 28Shareholder Returns
| NEO | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 25.1% | -0.9% | 0.8% |
| 1Y | -47.1% | -11.8% | 7.2% |
Return vs Industry: NEO underperformed the US Healthcare industry which returned -11.8% over the past year.
Return vs Market: NEO underperformed the US Market which returned 7.2% over the past year.
Price Volatility
| NEO volatility | |
|---|---|
| NEO Average Weekly Movement | 15.4% |
| Healthcare Industry Average Movement | 7.8% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: NEO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NEO's weekly volatility has increased from 10% to 15% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 2,200 | Tony Zook | www.neogenomics.com |
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
NeoGenomics, Inc. Fundamentals Summary
| NEO fundamental statistics | |
|---|---|
| Market cap | US$989.66m |
| Earnings (TTM) | -US$77.59m |
| Revenue (TTM) | US$672.36m |
1.5x
P/S Ratio-13.3x
P/E RatioIs NEO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NEO income statement (TTM) | |
|---|---|
| Revenue | US$672.36m |
| Cost of Revenue | US$374.48m |
| Gross Profit | US$297.88m |
| Other Expenses | US$375.47m |
| Earnings | -US$77.59m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.60 |
| Gross Margin | 44.30% |
| Net Profit Margin | -11.54% |
| Debt/Equity Ratio | 61.0% |
How did NEO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/07 23:43 |
| End of Day Share Price | 2025/05/07 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NeoGenomics, Inc. is covered by 28 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bruce Jackson | Benchmark Company |
| Raymond Myers | Benchmark Company |
| Michael Ryskin | BofA Global Research |